COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ALECTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN RESECTED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER IN THE CHINESE HEALTH CARE SYSTEM

被引：0
|
作者：
Wei, Q. [1 ]
Mao, J. [2 ]
Liang, Y. [2 ]
Guan, X. [2 ]
机构：
[1] Chinese Univ Hong Kong, Sch Pharm, Sha Tin, Hong Kong, Peoples R China
[2] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE167
引用
收藏
页码：S86 / S87
页数：2
相关论文
共 50 条
  • [31] Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer
    Goto, Yasushi
    Shukuya, Takehito
    Murata, Ai
    Kikkawa, Hironori
    Emir, Birol
    Wiltshire, Robin
    Miura, Satoru
    CANCER SCIENCE, 2023, 114 (06) : 2560 - 2568
  • [32] Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy
    Matsubara, Taichi
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Hamatake, Motoharu
    ANTICANCER RESEARCH, 2021, 41 (10) : 5157 - 5163
  • [33] Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
    Gadgeel, Shirish M.
    Shaw, Alice T.
    Govindan, Ramaswamy
    Gandhi, Leena
    Socinski, Mark A.
    Camidge, D. Ross
    De Petris, Luigi
    Kim, Dong-Wan
    Chiappori, Alberto
    Moro-Sibilot, Denis L.
    Duruisseaux, Michael
    Crino, Lucio
    De Pas, Tommaso
    Dansin, Eric
    Tessmer, Antje
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4079 - +
  • [34] Indirect treatment comparison of brigatinib versus alectinib for first-line treatment of ALK-positive non-small-cell lung cancer
    Thomas, M.
    Grohe, C.
    Waller, C.
    Ratsch, B.
    Basic, E.
    Brueckl, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 153 - 154
  • [35] COST-EFFECTIVENESS ANALYSIS OF ADJUVANTALECTINIB COMPARED TO PLATINUM-BASED ADJUVANTCHEMOTHERAPY IN PATIENTS WITH RESECTABLE ALK-POSITIVE NSCLC IN ITALY
    Paoletti, M.
    Scansetti, V
    Cazzato, D.
    Marcellusi, A.
    Belfiore, M.
    Isoko, J.
    Pacifici, M.
    Cortinovis, L. D.
    Veronesi, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [36] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY UNTREATED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
    Xie, J.
    Knoll, S.
    Slowley, A.
    Bensimon, A.
    Vieira, J.
    Chilcott, J.
    Paisley, S.
    Zhou, Z.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [37] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB AS ADJUVANT TREATMENT (MONOTHERAPY) FOR ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER FOLLOWING RESECTION AND PLATINUM-BASED CHEMOTHERAPY IN GREECE
    Nomikos, N.
    Naoum, P.
    Karampli, E.
    Jovanoski, N.
    Kakouros, M.
    Sideri-Papagianni, G.
    Kyriopoulos, I
    Pavi, E.
    Athanasakis, K.
    VALUE IN HEALTH, 2023, 26 (12) : S186 - S187
  • [38] Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer
    Wilner, Keith D.
    Usari, Tiziana
    Polli, Anna
    Kim, Elizabeth E.
    FUTURE ONCOLOGY, 2019, 15 (10) : 1097 - 1103
  • [39] The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer
    Gainor, Justin F.
    Ou, Sai-Hong Ignatius
    Logan, Jennifer
    Borges, Lawrence F.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1570 - 1573
  • [40] Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancer
    Rizzo, Alessandro
    THORACIC CANCER, 2023, 14 (13) : 1217 - 1217
12345